Biocom - Life Sciences Association of California
Close
Call
Profile
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo
cONTENT bLOCK
Left
Left
https://www.biocom.org/servlet/servlet.ImageServer?id=015F0000007NwSsIAK&oid=00DA0000000Kz7JMAS  

Generic Products: Opportunities for Southern California Companies

 
When:
Wednesday, August 09 2017 - Wednesday, August 09 2017
8:00 AM - 10:00 AM

Add to Calendar America/Los_Angeles Generic Products: Opportunities for Southern California Companies 8 in 10 of the 4.5 billion US prescriptions in 2016 were for generic drugs.  A generic drug is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. A generic drug is required to have the same active ingredient, strength, dosage form, and route of administration as the brand name product, but need not contain the same inactive ingredients.  It must, however, be proven to be bioequivalent to the brand name product.
 
BIOCOM - McGraw Boardroom Biocom false MM/DD/YYYY

Where:
BIOCOM - McGraw Boardroom
10996 Torreyana Road Suite 200
San Diego, California 92121
Registration Deadline:
Tuesday, August 08 2017
12:00 PM
Register


Event Overview:

8 in 10 of the 4.5 billion US prescriptions in 2016 were for generic drugs.  A generic drug is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. A generic drug is required to have the same active ingredient, strength, dosage form, and route of administration as the brand name product, but need not contain the same inactive ingredients.  It must, however, be proven to be bioequivalent to the brand name product.

If you are curious about the business drivers behind the generics industry, about the developmental and regulatory paths for a generic, about how bioequivalence can be proven, or about the strength of protection that a patent on an innovator product can provide, you might consider joining this event.

The event provides an introduction to the generics business in the US, overviewing business, technical, developmental, regulatory and commercial aspects. The event also includes examples of where formulation creativity can establish a basis for a generic approval.

Presenters:

"Generics - An Overview"
Giff Marzoni, Vice-President Global Pharmaceutical Development DavosPharma


"Navigating the Regulatory Paths for Generics"
Luman Wing, Director Executive Consultant, Cardinal Health


"Value Creation through Formulation of Generic Topicals"
John M Newsam, CEO Tioga Research

 
 

Sponsored By: